INTS - Intensity Therapeutics, Inc. Common stock

INTS - Intensity Therapeutics, Inc. Common stock

https://www.intensitytherapeutics.com

Recent News

Powered by Alpha Vantage

Why Intensity Therapeutics ( INTS ) Stock Is Getting Hammered - Intensity Therapeutics ( NASDAQ:INTS )

Benzinga • 4 months, 3 weeks ago • score: -0.01

Intensity Therapeutics shares are trading lower by 34.9% during Friday's session. The company announced the pricing of a public offering expected to raise approximately $2.35 million. Don't face extreme market conditions unprepared.

Is Cencora, Inc. ( COR ) Outperforming Other Medical Stocks This Year?

Zacks Commentary • 4 months, 3 weeks ago • score: 0.20

Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.

Has Cencora, Inc. ( COR ) Outpaced Other Medical Stocks This Year?

Zacks Commentary • 5 months, 1 week ago • score: 0.15

Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - ( ALMS )

Benzinga • 10 months, 2 weeks ago • score: 0.16

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird analyst Brian Skorney initiated coverage on Alumis Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$4.34

52W Low

$0.19

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

3.78

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-4.72

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

6.08

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

13.25%

Institutions (25–75% balanced)

6.87%

Shares Outstanding

47,057,700

Float

41,051,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-0.82

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-3.34%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—